Showing results (71-80 of 112) with videos related to
Sort By:
Pageof 12
Clinical Lung Cancer|August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.Targeted Oncology|March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.Nature Medicine|March 18, 2025
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancerRoy S Herbst, Thomas John, Christian Grohé, et al.The Lancet. Respiratory Medicine|October 24, 2017
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyMyung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, et al.Nature Cancer|February 5, 2022
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44Amy L Cummings, Jaklin Gukasyan, Henry Y Lu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2023
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational BurdenLuis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.Lancet (London, England)|October 9, 2019
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialLuis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.Pageof 12